Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

25%

5 trials in Phase 3/4

Results Transparency

31%

4 of 13 completed with results

Key Signals

4 with results93% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (2)
P 1 (6)
P 3 (5)

Trial Status

Completed13
Unknown3
Recruiting2
Enrolling By Invitation1
Terminated1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT00353158Phase 1Completed

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT01222741RecruitingPrimary

Studies of Disorders With Increased Susceptibility to Fungal Infections

NCT06483815Enrolling By InvitationPrimary

Fungal Infections During and After the SARS-CoV-2 Pandemic: A Retrospective Comparison

NCT05336851Recruiting

Emergency PWAS in Respiratory Infectious Disease

NCT00876096Not ApplicableCompleted

Interest of Real-time Polymerase Chain Reaction (PCR) in the Diagnosis of Fungal Infections

NCT01782131Phase 3CompletedPrimary

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

NCT02358499Phase 1CompletedPrimary

Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children

NCT03793231UnknownPrimary

fungalAi for Fungal Surveillance & Antifungal Stewardship

NCT02631954Phase 1Completed

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

NCT01716234Phase 1TerminatedPrimary

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

NCT01777763Phase 1CompletedPrimary

Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

NCT02025699Completed

Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis

NCT02306330Not ApplicableCompleted

MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial

NCT00794703Phase 3Completed

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

NCT01436578CompletedPrimary

Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)

NCT00606268Phase 1CompletedPrimary

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

NCT01684189Unknown

Registry of Febrile Neutropenia and Invasive Fungal Infections

NCT01105013Phase 3UnknownPrimary

Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections

NCT00177684Phase 3Completed

Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)

NCT00177710Phase 3Completed

Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study

Showing all 20 trials

Research Network

Activity Timeline